Skip to main content
KURA
NASDAQ Life Sciences

Kura Q3 10-Q: $13.9M KOMZIFTI Quarter, $492.1M Cash, New $275M Oberland Facility

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$7.2
Mkt Cap
$673.432M
52W Low
$6.75
52W High
$13.9
52W Position info
6.7% above low
Off High info
48% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

KURA is trading near its 52-week low of $6.75 (6.7% above the low).

Summary

Kura's Q3 10-Q confirms $13.9 million of KOMZIFTI revenue and $492.1 million in cash, and discloses a new $275.0 million Oberland debt facility plus a ziftomenib royalty agreement signed November 9, 2026.


Key Events · Earnings and Guidance · KURA

  • KOMZIFTI Revenue Reaches $13.9M

    Q3 2026 net product revenue was $13.9 million versus $9.1 million in Q2, and $28.8 million for the first nine months of 2026.

  • Cash of $492.1M at Quarter End

    Cash, cash equivalents and short-term investments totaled $492.1 million at September 30, 2026, down from $667.2 million at December 31, 2025; management says this funds operations into 2028.

  • New $275M Oberland Facility, $50M Drawn

    On November 9, 2026, Kura borrowed $50.0 million under a facility allowing up to $275.0 million across five tranches, with a $50.0 million tranche tied to positive KOMET-017 Phase 3 data, and repaid Hercules (~$11.6 million).

  • Ziftomenib Royalty Pledged to Oberland

    A royalty participation agreement requires quarterly single-digit royalties on U.S. ziftomenib net sales from October 1, 2028, capped at 20.0% of principal funded, running to November 9, 2036 at the latest.


Analysis · KURA · Life Sciences

The headline numbers were already out this evening, but the 10-Q adds the full balance sheet and, more importantly, the financing architecture behind the runway claim. On November 9, 2026, Kura closed a $275.0 million Oberland term loan, drew $50.0 million, and repaid Hercules. In exchange, it gave up a royalty on U.S. ziftomenib sales starting October 2028, capped at 20% of principal funded, and sold TPC 687,758 shares at $7.27 with up to $25.0 million more committed. Cash of $492.1 million plus $180.0 million of expected Kyowa Kirin milestones is what management says funds operations past the 2028 KOMET-017 readout. The quarter itself was clean on the top line — $13.9 million of KOMZIFTI revenue, up from $9.1 million — while R&D held flat at $66.9 million and the net loss narrowed to $70.2 million from $74.1 million a year ago. The Caspian spinout nets to zero in the P&L: a $30.6 million deconsolidation gain offset by a $30.6 million equity-method loss.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KURA was trading at $7.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $673.4M. The 52-week trading range was $6.75 to $13.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KURA - Latest Insights

KURA
Nov 10, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.29
Real-time Price: $7.86 info
Change: +$0.570 (+8%) info
Market Cap: $699.23M info
KURA
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.45
Real-time Price: $7.86 info
Change: +$0.410 (+6%) info
Market Cap: $699.23M info
KURA
Nov 10, 2026, 4:02 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.45
Real-time Price: $7.86 info
Change: +$0.410 (+6%) info
Market Cap: $699.23M info
KURA
Sep 29, 2026, 5:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.70
Real-time Price: $7.86 info
Change: -$2.84 (-27%) info
Market Cap: $699.23M info
KURA
Sep 09, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.64
Real-time Price: $7.86 info
Change: -$4.78 (-38%) info
Market Cap: $699.23M info